GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reunion Neuroscience Inc (TSX:REUN) » Definitions » Cyclically Adjusted Price-to-FCF

Reunion Neuroscience (TSX:REUN) Cyclically Adjusted Price-to-FCF : (As of Apr. 27, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Reunion Neuroscience Cyclically Adjusted Price-to-FCF?

Reunion Neuroscience does not have a history long enough to calculate Cyclically Adjusted FCF per Share. Therefore GuruFocus does not calculate Cyclically Adjusted Price-to-FCF for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Reunion Neuroscience Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Reunion Neuroscience's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reunion Neuroscience Cyclically Adjusted Price-to-FCF Chart

Reunion Neuroscience Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted Price-to-FCF
- - - -

Reunion Neuroscience Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Reunion Neuroscience's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Reunion Neuroscience's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reunion Neuroscience's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reunion Neuroscience's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Reunion Neuroscience's Cyclically Adjusted Price-to-FCF falls into.



Reunion Neuroscience Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Reunion Neuroscience does not have a history long enough to calculate Cyclically Adjusted FCF per Share. Therefore GuruFocus does not calculate Cyclically Adjusted Price-to-FCF for this company.


Reunion Neuroscience  (TSX:REUN) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Reunion Neuroscience Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Reunion Neuroscience's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Reunion Neuroscience (TSX:REUN) Business Description

Traded in Other Exchanges
N/A
Address
30 Duncan Street, Lower North Suite, Toronto, ON, CAN, M5V 2C3
Reunion Neuroscience Inc is engaged in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company's asset, RE-104 (previously known as FT-104), is a proprietary, novel psychedelic drug being developed for post-partum and treatment-resistant depression as a potential fast-acting antidepressant with durable efficacy.

Reunion Neuroscience (TSX:REUN) Headlines

From GuruFocus